Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control

Julio I. Osende, Juan Jose Badimon, Valentin Fuster, Perry Herson, Phil Rabito, Ramapriya Vidhun, Azfar Zaman, Oswaldo J. Rodriguez, Eli I. Lev, Ursula Rauch, Gerard Heflt, John T. Fallon, Jill P. Crandall

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

OBJECTIVES: This study was designed to determine whether blood thrombogenicity is related to chronic glycemic control in type 2 diabetes mellitus (T2DM). BACKGROUND: Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications. Whether increased blood thrombogenicity is associated with glycemic control has not been properly tested. METHODS: Forty patients with T2DM with hemoglobin A1c (HbA1c) ≥7.5% were selected. Maintaining their current hypoglycemic therapies, patients were randomized into a conservative (diet modification plus placebo) or intensive (diet modification plus troglitazone) hypoglycemic regimen for three months. Blood thrombogenicity was measured at baseline and after three months with the Badimon ex vivo perfusion chamber and assessed as platelet-thrombus formation. The repeated measurements allowed every patient to be his/her own control. RESULTS: Patients in both groups (48% and 74% of the conservative and intensive groups, respectively) improved glucose control (HbA1c reduction ≥0.5%), showing a significant decrease in blood thrombogenicity. A significant positive correlation was observed between the reduction in thrombus formation and the reduction in HbA1c (r = 0.47, p < 0.01). The reduction in HbA1c achieved by both treatments was comparable. Patients without glycemic improvement showed no change in blood thrombogenicity. Improved glycemic control was the only significant predictor of a decrease in blood thrombogenicity. CONCLUSIONS: In T2DM, there is an association between improved glycemic control and blood thrombogenicity reduction. The effect of glycemic control on the thrombotic complications of T2DM patients deserves further investigation.

Original languageEnglish (US)
Pages (from-to)1307-1312
Number of pages6
JournalJournal of the American College of Cardiology
Volume38
Issue number5
DOIs
StatePublished - Nov 1 2001
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Hemoglobins
Diet Therapy
troglitazone
Hypoglycemic Agents
Thrombosis
Diabetes Complications
Atherosclerosis
Blood Platelets
Perfusion
Placebos
Glucose
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. / Osende, Julio I.; Badimon, Juan Jose; Fuster, Valentin; Herson, Perry; Rabito, Phil; Vidhun, Ramapriya; Zaman, Azfar; Rodriguez, Oswaldo J.; Lev, Eli I.; Rauch, Ursula; Heflt, Gerard; Fallon, John T.; Crandall, Jill P.

In: Journal of the American College of Cardiology, Vol. 38, No. 5, 01.11.2001, p. 1307-1312.

Research output: Contribution to journalArticle

Osende, JI, Badimon, JJ, Fuster, V, Herson, P, Rabito, P, Vidhun, R, Zaman, A, Rodriguez, OJ, Lev, EI, Rauch, U, Heflt, G, Fallon, JT & Crandall, JP 2001, 'Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control', Journal of the American College of Cardiology, vol. 38, no. 5, pp. 1307-1312. https://doi.org/10.1016/S0735-1097(01)01555-8
Osende, Julio I. ; Badimon, Juan Jose ; Fuster, Valentin ; Herson, Perry ; Rabito, Phil ; Vidhun, Ramapriya ; Zaman, Azfar ; Rodriguez, Oswaldo J. ; Lev, Eli I. ; Rauch, Ursula ; Heflt, Gerard ; Fallon, John T. ; Crandall, Jill P. / Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. In: Journal of the American College of Cardiology. 2001 ; Vol. 38, No. 5. pp. 1307-1312.
@article{9bd446cbe3f040879533a822e68039ad,
title = "Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control",
abstract = "OBJECTIVES: This study was designed to determine whether blood thrombogenicity is related to chronic glycemic control in type 2 diabetes mellitus (T2DM). BACKGROUND: Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications. Whether increased blood thrombogenicity is associated with glycemic control has not been properly tested. METHODS: Forty patients with T2DM with hemoglobin A1c (HbA1c) ≥7.5{\%} were selected. Maintaining their current hypoglycemic therapies, patients were randomized into a conservative (diet modification plus placebo) or intensive (diet modification plus troglitazone) hypoglycemic regimen for three months. Blood thrombogenicity was measured at baseline and after three months with the Badimon ex vivo perfusion chamber and assessed as platelet-thrombus formation. The repeated measurements allowed every patient to be his/her own control. RESULTS: Patients in both groups (48{\%} and 74{\%} of the conservative and intensive groups, respectively) improved glucose control (HbA1c reduction ≥0.5{\%}), showing a significant decrease in blood thrombogenicity. A significant positive correlation was observed between the reduction in thrombus formation and the reduction in HbA1c (r = 0.47, p < 0.01). The reduction in HbA1c achieved by both treatments was comparable. Patients without glycemic improvement showed no change in blood thrombogenicity. Improved glycemic control was the only significant predictor of a decrease in blood thrombogenicity. CONCLUSIONS: In T2DM, there is an association between improved glycemic control and blood thrombogenicity reduction. The effect of glycemic control on the thrombotic complications of T2DM patients deserves further investigation.",
author = "Osende, {Julio I.} and Badimon, {Juan Jose} and Valentin Fuster and Perry Herson and Phil Rabito and Ramapriya Vidhun and Azfar Zaman and Rodriguez, {Oswaldo J.} and Lev, {Eli I.} and Ursula Rauch and Gerard Heflt and Fallon, {John T.} and Crandall, {Jill P.}",
year = "2001",
month = "11",
day = "1",
doi = "10.1016/S0735-1097(01)01555-8",
language = "English (US)",
volume = "38",
pages = "1307--1312",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control

AU - Osende, Julio I.

AU - Badimon, Juan Jose

AU - Fuster, Valentin

AU - Herson, Perry

AU - Rabito, Phil

AU - Vidhun, Ramapriya

AU - Zaman, Azfar

AU - Rodriguez, Oswaldo J.

AU - Lev, Eli I.

AU - Rauch, Ursula

AU - Heflt, Gerard

AU - Fallon, John T.

AU - Crandall, Jill P.

PY - 2001/11/1

Y1 - 2001/11/1

N2 - OBJECTIVES: This study was designed to determine whether blood thrombogenicity is related to chronic glycemic control in type 2 diabetes mellitus (T2DM). BACKGROUND: Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications. Whether increased blood thrombogenicity is associated with glycemic control has not been properly tested. METHODS: Forty patients with T2DM with hemoglobin A1c (HbA1c) ≥7.5% were selected. Maintaining their current hypoglycemic therapies, patients were randomized into a conservative (diet modification plus placebo) or intensive (diet modification plus troglitazone) hypoglycemic regimen for three months. Blood thrombogenicity was measured at baseline and after three months with the Badimon ex vivo perfusion chamber and assessed as platelet-thrombus formation. The repeated measurements allowed every patient to be his/her own control. RESULTS: Patients in both groups (48% and 74% of the conservative and intensive groups, respectively) improved glucose control (HbA1c reduction ≥0.5%), showing a significant decrease in blood thrombogenicity. A significant positive correlation was observed between the reduction in thrombus formation and the reduction in HbA1c (r = 0.47, p < 0.01). The reduction in HbA1c achieved by both treatments was comparable. Patients without glycemic improvement showed no change in blood thrombogenicity. Improved glycemic control was the only significant predictor of a decrease in blood thrombogenicity. CONCLUSIONS: In T2DM, there is an association between improved glycemic control and blood thrombogenicity reduction. The effect of glycemic control on the thrombotic complications of T2DM patients deserves further investigation.

AB - OBJECTIVES: This study was designed to determine whether blood thrombogenicity is related to chronic glycemic control in type 2 diabetes mellitus (T2DM). BACKGROUND: Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications. Whether increased blood thrombogenicity is associated with glycemic control has not been properly tested. METHODS: Forty patients with T2DM with hemoglobin A1c (HbA1c) ≥7.5% were selected. Maintaining their current hypoglycemic therapies, patients were randomized into a conservative (diet modification plus placebo) or intensive (diet modification plus troglitazone) hypoglycemic regimen for three months. Blood thrombogenicity was measured at baseline and after three months with the Badimon ex vivo perfusion chamber and assessed as platelet-thrombus formation. The repeated measurements allowed every patient to be his/her own control. RESULTS: Patients in both groups (48% and 74% of the conservative and intensive groups, respectively) improved glucose control (HbA1c reduction ≥0.5%), showing a significant decrease in blood thrombogenicity. A significant positive correlation was observed between the reduction in thrombus formation and the reduction in HbA1c (r = 0.47, p < 0.01). The reduction in HbA1c achieved by both treatments was comparable. Patients without glycemic improvement showed no change in blood thrombogenicity. Improved glycemic control was the only significant predictor of a decrease in blood thrombogenicity. CONCLUSIONS: In T2DM, there is an association between improved glycemic control and blood thrombogenicity reduction. The effect of glycemic control on the thrombotic complications of T2DM patients deserves further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0035499206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035499206&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(01)01555-8

DO - 10.1016/S0735-1097(01)01555-8

M3 - Article

C2 - 11691500

AN - SCOPUS:0035499206

VL - 38

SP - 1307

EP - 1312

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -